Italia markets closed
FTSE MIB
35.398,82 -11,31 (-0,03%) Dow Jones
39.900,11 +30,73 (+0,08%) Nasdaq
16.690,43 -7,89 (-0,05%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,47 +0,24 (+0,30%) Bitcoin EUR
61.857,79 +1.711,04 (+2,84%)
NBIX May 2024 110.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:44PM EDT. Mercato aperto.
| Chiusura precedente | 1,9500 |
| Aperto | 1,9500 |
| Denaro | 0,4500 |
| Lettera | 1,0000 |
| Prezzo d'esercizio | 110,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,9500 - 1,9500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 5 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.